Teva And Royalty Pharma Announce $500M Collaboration To Advance TEV-‘408 For Vitiligo After Promising Early Data; Further Readouts In 2026

Royalty Pharma plc and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that they have entered into a funding agreement of up to $500 million. The purpose of this collaboration is to support and accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-‘408. IL-15 is an important cytokine that plays a central role in several immune-mediated disease pathways. 

Because of its influence on the immune system, IL-15 has become an area of interest for new therapies aimed at treating autoimmune conditions. In Teva’s ongoing Phase 1b study of TEV-‘408 for vitiligo, early data has shown encouraging signs. These initial findings suggest that targeting IL-15 may offer a new therapeutic approach for a variety of autoimmune diseases beyond vitiligo. Teva expects to share additional results from its TEV-‘408 trials in 2026.

Pablo Legorreta, Chief Executive Officer and Chairman of the Board at Royalty Pharma, said the company is pleased to enter into a second collaboration with Teva as they continue developing TEV-‘408. He noted that vitiligo is a long-term autoimmune skin disease that can significantly affect a person’s emotional and social well-being. Despite this impact, available treatments remain limited. Legorreta explained that the ongoing partnership reflects Royalty Pharma’s commitment to supporting innovation and helping advance therapies that have the potential to meaningfully improve patient care.

Richard Francis, President and CEO of Teva, emphasized that partnerships are an important driver of scientific progress. He explained that working with Royalty Pharma will allow Teva to advance its research more efficiently and accelerate the development of therapies within its pipeline. Francis pointed out that vitiligo continues to be an area of high unmet need, with only one approved topical treatment and no systemic options available today. He added that Teva remains focused on developing new therapeutic solutions that can make a real difference for people living with chronic autoimmune diseases.